Longeveron Inc.（LGVN）股價、財務與研究

盤中時間採用ET。市場資料可能有所延遲。

GoAI 研究快照

簡明呈現最新可用的模型資訊。

2026年7月10日

31/ 100

GoAI評分

Sell

Trim exposure — unfavorable risk-reward

估值

32

Expensive

動能

28

Weakening

情緒

50

Mixed

風險韌性

34

High Risk

完整 GoAI 研究

繼續查看更深入的依據、催化因素和風險。

看完整研究

人工智慧產生的上下文僅供參考，並非投資建議。

公司概況

公司網站

Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.

產業: Biotechnology
部門: Healthcare
總部: US
執行長: Stephen H. Willard
上市以來: 2021年2月12日
僱員: 38

市場位置

日內區間

目前US$0.8378，

US$0.8147US$0.85

52週區間

目前US$0.8378，

US$0.475US$1.23

開盤價: US$0.85
前收盤價: US$0.8449
成交量: 77.16萬; 1.95× 平均值
平均成交量: 39.53萬; 日均成交量
市值: 1670.11萬 USD
貝塔: -0.25; 市場參考 1
50天平均值: US$0.7091; 高於平均水平+18.15%
200天平均值: US$0.7219; 高於平均水平+16.06%

財務數據

財務快照

估值與收益率

企業價值: 505.67萬 USD
本益比（TTM）: -0.83×
股價淨值比（TTM）: 2.53×
股價營收比（TTM）: 14.07×
EV/EBITDA: -0.24×
盈餘收益率: -255.28%
自由現金流收益率: -212.40%
股息率: 0.00%

獲利能力和效率

毛利率: 69.76%
營業利益率: -1992.84%
淨利潤率: -1977.59%
股東權益報酬率: -400.07%
資產報酬率: -221.26%
投入資本報酬率: -341.00%

財務健康

負債權益比: 0.06×
流動比率: 1.33×

財報歷史與展望

EPS優於預期率: 36%; 優於預期4次、低於預期5次、符合預期2次
平均EPS意外幅度: -6.07%; 11 類似報告
最新每股收益結果: -0.19; 預估-0.18 · 低於預期8.57%

EPS：實際值與預估值

近期已公布業績

實際值預估值

營收：實際值與預估值

近期已公布業績

實際值預估值

分析師評級

第三方分析師預期可能變動，並非 GoAI 建議。

分析師目標價

平均目標

US$10.00

上漲空間 1093.60%

過去 12 個月12個月預測最高：US$10.00平均的：US$10.00最低：US$10.00

近期分析師行動

3 機構

Roth CapitalmaintainBuy2025年8月15日

LGVN 訊息

globenewswire.com2026年8月24日

Longeveron Announces 1-for-10 Reverse Stock Split

MIAMI, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today…

閱讀原始碼

globenewswire.com2026年8月19日

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Mr. Jhaveri has over 25 years of experience in capital markets, corporate finance, business development and investor relations, including more than 15 years in the biotech sector MIAMI, Aug. 19, 2026 (GLOBE NEWSWIRE) --…

閱讀原始碼

seekingalpha.com2026年8月13日

Longeveron Inc. (LGVN) Q2 2026 Earnings Call Transcript

閱讀原始碼

globenewswire.com2026年8月12日

Longeveron Announces 2026 Second Quarter Financial Results and Provides Business Update

On track for September 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome (HLHS), a rare pediatric disease and…

閱讀原始碼

globenewswire.com2026年8月11日

Longeveron Named a Finalist Team and Will Receive a $1,000,000 Milestone 2 Award for the XPRIZE Healthspan Global Competition

Longeveron selected as a Milestone 2 Awardee based on published clinical trial results which demonstrated laromestrocel increased 6-minute walk distance in patients with Aging-related Frailty MIAMI, Aug. 11, 2026 (GLOBE…

閱讀原始碼

globenewswire.com2026年8月3日

Longeveron to Report 2026 Second Quarter Financial Results and Host Conference Call on August 12, 2026

MIAMI, Fla., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related…

閱讀原始碼